Syndax Pharmaceuticals Inc’s recently made public that its Chief Executive Officer Metzger Michael A unloaded Company’s shares for reported $2.58 million on Sep 08 ’25. In the deal valued at $16.41 per share,157,307 shares were sold. As a result of this transaction, Metzger Michael A now holds 298,661 shares worth roughly $4.76 million.
Then, MICHAEL METZGER bought 157,307 shares, generating $2,680,511 in total proceeds.
Before that, Podlesak Dennis sold 19,200 shares. Syndax Pharmaceuticals Inc shares valued at $304,170 were divested by the Director at a price of $15.84 per share. As a result of the transaction, Podlesak Dennis now holds 191,763 shares, worth roughly $3.05 million.
A number of analysts have revised their coverage, including BTIG Research’s analysts, who remained covering the stock and in early August has reiterated a ‘”a Buy”‘ rating for it. Goldman began covering SNDX with “Buy” recommendation on July 10, 2025. UBS started covering the stock on October 24, 2024. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock fall -2.45% to $15.93. Over the last five days, the stock has lost -1.18%. Syndax Pharmaceuticals Inc shares have fallen nearly -18.72% since the year began. Nevertheless, the stocks have risen 20.50% over the past one year. While a 52-week high of $22.50 was reached on 08/28/25, a 52-week low of $8.58 was recorded on 05/15/25.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 15.66, which if violated will result in even more drops to 15.38. On the upside, there is a resistance level at 16.26. A further resistance level may holdings at 16.58.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2025-08-15, dropping by -3.09 million shares to a total of 20.61 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 23.69 million shares. There was a decline of -14.97%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 28, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $37 price target.
